A/Professor Camilo Jimenez

Dr. Jimenez is an Associate Professor for the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center. Dr. Jimenez is the Head of the Adrenal section and has performed extensive clinical research in the field of endocrine cancer with a particular interest in pheochromocytomas and paragangliomas. Dr. Jimenez was one of the first clinicians to describe the use of tyrosine kinase inhibitors in patients affected with sporadic and hereditary malignant pheochromocytomas/paragangliomas. His observations have led to the development of prospective multi-institutional, international clinical trials that target different hallmarks of this disease. He is the principal investigator of phase 2 clinical trials with tyrosine kinase inhibitors, such as cabozantinib, pazopanib, and immunotherapies such as pembrolizumab.  He is currently the senior principal investigator of the Pivotal Phase 2 study of Ultratrace Iobenguane Iodine 131 in Patients with Malignant Relapsed/Refractory. Preliminary results of this study are very favorable and the FDA has designated this medication as a breakthrough therapy. Dr. Jimenez has published more than 100 manuscripts in indexed journals and chapters for prestigious books, including Harrison’s Principles of Internal Medicine. He was a member of the editorial board for the Journal of Clinical Endocrinology and Metabolism. Additionally, Dr. Jimenez has lectured in many national and international scientific meetings and served as chair of the International Society for Pheochromocytoma and Paraganglioma Research PRESSOR 2011-2014. Dr. Jimenez received the 2015 PheoPara Alliance Science Award for his contributions to the development of novel therapeutic modalities for patients with malignant pheochromocytomas/paragangliomas.  In 2016, the American Joint Committee in Cancer commissioned Dr. Jimenez and other scientists to develop the first TNM staging for patients with pheochromocytomas/paragangliomas. His very focused and successful career has positioned him to be followed by the new generations of endocrinologists.  Emblematic of this success, the Endocrine Society invited him four years in succession, to give the honorary lecture titled “How I got here? A personal journey”. 


Supported By